Suppr超能文献

磁共振成像筛查在1型神经纤维瘤病儿童视路胶质瘤中的应用

The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

作者信息

Prada Carlos E, Hufnagel Robert B, Hummel Trent R, Lovell Anne M, Hopkin Robert J, Saal Howard M, Schorry Elizabeth K

机构信息

Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH; Center for Genomic Medicine and Metabolism, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.

Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH.

出版信息

J Pediatr. 2015 Oct;167(4):851-856.e1. doi: 10.1016/j.jpeds.2015.07.001. Epub 2015 Jul 29.

Abstract

OBJECTIVE

To evaluate the utility of screening brain/orbital magnetic resonance imaging (MRI) in a large population of children with neurofibromatosis type 1 (NF1) over a 20-year period.

STUDY DESIGN

A retrospective analysis of clinical and imaging data from children with NF1 seen at a single center between 1990 and 2010 was performed.

RESULTS

During the 20-year study period, 826 individuals with NF1 (402 females, 424 males) ages 1-9 years were screened for optic pathway gliomas (OPGs) using brain/orbital MRI; 18% were identified with OPGs with a median age at detection of 3 years. Fifteen percent of patients with OPGs had radiologic or clinical progression requiring therapy. Children with chiasmatic and postchiasmatic tumors were more likely to require therapy compared with patients with prechiasmatic OPGs (P < .0001). Patients with visual deficits at the time of diagnosis were more likely to experience visual decline despite therapy when compared with patients treated based on radiologic progression (P < .012).

CONCLUSIONS

Our findings confirm that chiasmatic and postchiasmatic OPG in children with NF1 have the highest risk for progression and vision loss. Early identification of OPG by screening MRI prior to the development of vision loss may lead to improved visual outcomes. Children with negative brain and orbital MRI screening at age 15 months or later did not develop symptomatic OPGs.

摘要

目的

评估在20年期间对大量1型神经纤维瘤病(NF1)儿童进行脑/眼眶磁共振成像(MRI)筛查的效用。

研究设计

对1990年至2010年在单一中心就诊的NF1儿童的临床和影像数据进行回顾性分析。

结果

在20年的研究期间,对826名年龄在1至9岁的NF1患者(402名女性,424名男性)进行了脑/眼眶MRI检查以筛查视神经通路胶质瘤(OPG);18%的患者被确诊患有OPG,确诊时的中位年龄为3岁。15%的OPG患者出现了需要治疗的影像学或临床进展。与视交叉前OPG患者相比,视交叉和视交叉后肿瘤的儿童更有可能需要治疗(P < .0001)。与基于影像学进展接受治疗的患者相比,诊断时存在视力缺陷的患者在接受治疗后更有可能出现视力下降(P < .012)。

结论

我们的研究结果证实,NF1儿童的视交叉和视交叉后OPG进展和视力丧失的风险最高。在视力丧失发生之前通过筛查MRI早期发现OPG可能会改善视力预后。15个月及以后脑和眼眶MRI筛查结果为阴性的儿童未出现有症状的OPG。

相似文献

1
The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
J Pediatr. 2015 Oct;167(4):851-856.e1. doi: 10.1016/j.jpeds.2015.07.001. Epub 2015 Jul 29.
2
Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
J AAPOS. 2010 Apr;14(2):155-8. doi: 10.1016/j.jaapos.2009.11.020.
3
Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
J Neuroophthalmol. 2017 Sep;37 Suppl 1(Suppl 1):S23-S32. doi: 10.1097/WNO.0000000000000550.
6
The role of surgery in optic pathway/hypothalamic gliomas in children.
J Neurosurg Pediatr. 2014 Jan;13(1):1-12. doi: 10.3171/2013.8.PEDS12546. Epub 2013 Oct 18.

引用本文的文献

1
Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study.
Cancers (Basel). 2025 Apr 23;17(9):1404. doi: 10.3390/cancers17091404.
3
Expanding the phenotype of neurofibromatosis type 1 microdeletion syndrome.
Am J Med Genet C Semin Med Genet. 2024 Dec;196(4):e32095. doi: 10.1002/ajmg.c.32095. Epub 2024 Jul 18.
7
The Neuroimmune Regulation and Potential Therapeutic Strategies of Optic Pathway Glioma.
Brain Sci. 2023 Oct 7;13(10):1424. doi: 10.3390/brainsci13101424.
8
Pediatric Optic Pathway Gliomas Resource Utilization and Prevalence in the OptumLabs Data Warehouse.
J Neuroophthalmol. 2024 Mar 1;44(1):10-15. doi: 10.1097/WNO.0000000000001960. Epub 2023 Jul 28.
9
Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.
Cancer Manag Res. 2023 Jul 13;15:667-681. doi: 10.2147/CMAR.S362678. eCollection 2023.

本文引用的文献

1
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.
Ann Neurol. 2014 Feb;75(2):309-16. doi: 10.1002/ana.24093. Epub 2014 Feb 6.
3
Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.
Neuro Oncol. 2012 Feb;14(2):160-74. doi: 10.1093/neuonc/nor206. Epub 2012 Jan 10.
6
Natural history and management of low-grade glioma in NF-1 children.
J Neurooncol. 2010 Nov;100(2):199-207. doi: 10.1007/s11060-010-0159-z. Epub 2010 Mar 30.
7
Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1309-17. doi: 10.1007/s00259-010-1386-4. Epub 2010 Feb 24.
8
Natural history and outcome of optic pathway gliomas in children.
Pediatr Blood Cancer. 2009 Dec 15;53(7):1231-7. doi: 10.1002/pbc.22198.
9
Optic pathway gliomas: a review.
Neurosurg Focus. 2007;23(5):E2. doi: 10.3171/FOC-07/11/E2.
10
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Ann Neurol. 2007 Mar;61(3):189-98. doi: 10.1002/ana.21107.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验